Ulonivirine - Merck Sharp & Dohme
Alternative Names: MK-8507Latest Information Update: 14 Feb 2024
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Antiretrovirals; Benzonitrile; Chlorinated hydrocarbons; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyrimidines
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 14 Feb 2024 Chemical structure information added
- 28 Sep 2022 No recent reports of development identified for phase-I development in HIV-1-infections(Treatment-naive) in Germany (PO, Tablet)
- 18 Nov 2021 Merck suspends dosing in the phase II IMAGINE-DR trial for HIV-1 infections (Combination therapy) in France, Switzerland and USA